Barclays PLC Takes $255,000 Position in Bicara Therapeutics Inc. (NASDAQ:BCAX)

Barclays PLC bought a new stake in shares of Bicara Therapeutics Inc. (NASDAQ:BCAX) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 10,000 shares of the company’s stock, valued at approximately $255,000.

A number of other hedge funds also recently added to or reduced their stakes in BCAX. First Turn Management LLC purchased a new position in Bicara Therapeutics in the 3rd quarter worth approximately $14,324,000. The Manufacturers Life Insurance Company purchased a new position in Bicara Therapeutics in the 3rd quarter worth approximately $582,000. FMR LLC purchased a new position in Bicara Therapeutics in the 3rd quarter worth approximately $57,913,000. Walleye Capital LLC purchased a new position in Bicara Therapeutics in the 3rd quarter worth approximately $809,000. Finally, Vestal Point Capital LP purchased a new stake in Bicara Therapeutics during the 3rd quarter valued at $10,825,000.

Bicara Therapeutics Stock Down 1.4 %

Shares of Bicara Therapeutics stock opened at $16.69 on Monday. The business has a fifty day moving average price of $20.10. Bicara Therapeutics Inc. has a fifty-two week low of $16.01 and a fifty-two week high of $28.09.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($1.60) EPS for the quarter, missing the consensus estimate of ($0.46) by ($1.14). On average, sell-side analysts forecast that Bicara Therapeutics Inc. will post -2.59 EPS for the current year.

Wall Street Analysts Forecast Growth

A number of equities research analysts have weighed in on the stock. TD Cowen assumed coverage on shares of Bicara Therapeutics in a research note on Tuesday, October 8th. They set a “buy” rating for the company. Morgan Stanley initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set an “overweight” rating and a $35.00 price objective for the company. RODMAN&RENSHAW raised shares of Bicara Therapeutics to a “strong-buy” rating in a research report on Tuesday, November 5th. Stifel Nicolaus initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, October 8th. They set a “buy” rating and a $47.00 price objective for the company. Finally, Rodman & Renshaw initiated coverage on shares of Bicara Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating and a $48.00 price objective for the company. Six equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, Bicara Therapeutics presently has an average rating of “Buy” and a consensus target price of $43.00.

About Bicara Therapeutics

Bicara Therapeutics Inc, a clinical-stage biopharmaceutical company, develops bifunctional therapies for solid tumors. Its lead program is ficerafusp alfa, a bifunctional antibody that combines an epidermal growth factor receptor (EGFR) directed monoclonal antibody with a domain that binds to human transforming growth factor beta (TGF-b) for the treatment of solid tumors.